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Dynamics of  HIV-1 Associated Kaposi Sarcoma  
During HAART Therapy 
 
Frank Nani and Mingxian Jin 
Department of Mathematics and Computer Science 
Fayetteville State University, Fayetteville, NC 28301, USA 
 
 
Abstract –The techniques of mathematical modeling and 
investigative computer simulations are used to study the 
qualitative aspects of the patho-physiodynamics of HIV-1 
associated Kaposi sarcoma (KS) during Highly Active 
Anti-Retroviral Therapy (HAART) of AIDS. Using a system of 
non-linear deterministic differential equations, the model 
incorporates the biologically measurable and clinically 
relevant immunological interactions and parameters. In 
particular, the computer simulations elucidate the role of 
CD8+ T lymphocyte in the annihilation and persistence of 
Kaposi sarcoma during HAART.  
Keywords: Kaposi sarcoma, mathematical modeling, 
HAART efficacy, computer simulations, persistence of 
Kaposi Sarcoma 
 
1 Introduction 
Human Herpes Virus 8 (HHV8) acts in association with 
HIV-1 to induce lympho-proliferation and Kaposi sarcoma 
(KS) in AIDS patients. The clinical and histo-pathological 
aspects of KS have been documented by Kemény et al. [3],  
Lesbordes et al. [5], and Zhu et al. [11].  
The role of CD8+ T lymphocytes in regulating the 
growth of KS has been investigated by Li et al. [6] and 
Stebbing et al [8]. The use of adoptive immunotherapy with 
activated autologous CD8+ T cells with interleukin-2 infusion 
in treatment of AIDS was described in a paper by Klimas et al. 
[4], Touloumi et al. [9], and Urassa et al. [10]. The 
patho-physio-dynamics of KS during HAART has been 
clinically investigated by Bihl et al. [1], and Dupont et al. [2].  
In the current research, we shall present a mathematical 
model of the patho-physio-dynamics of KS associated with 
AIDS during HAART. This paper is extension of our earlier 
mathematical model on HIV-1 AIDS dynamics during 
latency phase [7]. Investigative computer simulations will be 
used to elucidate the effect of adoptive transfer of CD8+ T 
cells on Kaposi sarcoma dynamics during HAART. This 
research is one of the major attempts to construct a clinically 
plausible mathematical model which incorporates HAART 
therapy, HIV-1 induced AIDS dynamics, and Kaposi 
sarcoma.  
 
2 Parameters 
In this section, the model parameters, constants, and 
variables are presented as modified from [7].  
x1: the number density of non-HIV-1-infected CD4+ helper 
T-lymphocytes per unit volume at any time t  
x2: the number density of HIV-1 infected CD4+ helper 
T-lymphocytes per unit volume at any time t 
x3: the number density of HIV-1 virions in the blood plasma 
per unit volume at any time t 
x4: the number density of HIV-1 specific CD8+ cytotoxic 
T-lymphocytes per unit volume at any time t 
x5: the concentration of drug molecules of the HAART 
treatment protocol at any time t 
x6:The number of Kaposi sarcoma cancer cells in the AIDS 
patient at any time t during HAART 
S1:  rate of supply of un-infected CD4+ T4-lymphocytes  
S2:  rate of supply of latently infected CD4+ T4-lymphocytes 
S3: rate of supply of HIV-1 virions from macrophage, 
monocytes, microglial cells and other lymphoid tissue 
different from T4-lymphocytes 
S4:  rate of supply of CD8+  T8 lymphocytes from the thymus 
D:  rate of HAART drug infusion by transdermal delivery   
ai, bi: constant associated with activation of lymphocytes by 
cytokine interleukin-2 (IL-2) (i =1, 2, 3, 4) 
αi: constant associated with HIV-1 infection of CD4+ T4 
helper cells (i =1, 2, 3) 
β1: the number of HIV-1 virions produced per day by 
replication and budding in CD4+ T4 helper cells  
β2: rate constant associated with replication and “budding” of 
HIV-1 in syncytia CD4+ T4 helper cells per day per 
microliter (μl) and released into the blood plasma  
β3: the number of HIV-1 virions produced per day by 
replication and “budding” in non-syncytia CD4+ T4 helper 
cells and released into the blood plasma 
ηi: constant depicting the rate of which HIV-1 virions 
incapacitate the CD8+ T8 cytotoxic cells (i =1, 2) 
(σ0, λ0): Michaelis-Menten metabolic rate constants 
associated with HAART drug elimination 
(σi, λi): Michaelis-Menten metabolic rate constants 
associated with HAART drug pharmacokinetics (i =2, 3) 
(σ4, λ4): Michaelis-Menten metabolic rate constants 
associated with cytolytic action of CD8+ against Kaposi 
Sarcoma cancer cells 
γ4: constant depicting the cytolytic efficacy of CD8+ T cells 
against Kaposi sarcoma cancer cells 
ξi: cytotoxic coefficient where 0 ≤ ξi  ≤ 1 (i =  2, 3) 
qi: constant depicting competition between infected and 
un-infected CD4+ T4 helper cells (i =1, 2) 
ki: constant depicting degradation, loss of clonogenicity or  
“death” (i =1, 2, 3, 4) 
ei0: constant depicting death or degradation or removal by 
apoptosis (programmed cell death) (i =1, 2, 3, 4) 
Ki: constant associated with the killing rate of infected CD4+ 
T4 cells by CD8+  T8 cytotoxic lymphocytes (i =1, 2) 
All the parameters are positive 
ci: kinetic constants depicting logistic tumor growth for 
Kaposi sarcoma 
3 Model Equations 
 The following system of non-linear deterministic 
ordinary differential equations models the 
patho-physiological dynamics of HIV-1 induced AIDS 
virions and associated Kaposi sarcoma cancer cells, CD4+ 
(infected and non-infected) T cells, and CD8+ T cells during 
HAART therapy.
      
     
 
 
 
 
 
 
 
 
                        
 
 
   (3.1) 
4 Simulation results and discussion 
A brief summary of the simulation results will be 
presented in this section. Figure 1 and Figure 2 correspond 
respectively to hypothetical HIV-1 KS patient’s physiological 
parametric configurations P1 (Table 1) and P2 (Table 2).  
(i) Hypothetical clinical case #1[Figure 1, P1]: 
It is observed that HAART treatment successfully 
annihilates the HIV-1 virions in the blood plasma and 
reduces the number density of HIV-1 infected CD4+ T cells, 
whereas the non-infected CD4+ T cells proliferate to 
clinically efficacious levels. On the other hand, the HIV-1 
specific CD8+ T cells are eliminated and consequently the 
Kaposi sarcoma proliferates out of control. 
 
(ii) Hypothetical clinical case #2 [Figure 1, P1′]: 
In this scenario, the physiological parametric configuration 
is the same as that of P1 except that there is an adoptive 
transfer of 2000 units of ex-vivo interlenkin-2 activated 
CD8+ cytotoxic T cells. In P1′, the S4 value is now assigned 
to a value of 2000 instead of 10 as in P1. The therapeutic 
outcome is clinically efficacious because the Kaposi 
sarcoma is annihilated.  
(iii) Hypothetical clinical case #3[Figure 2, P2]: 
This scenario discusses the effect of HIV-1 latent viral 
reservoirs on the treatment outcome. In particular, S3 is set 
to a value of 1000, depicting the influx of 1000 HIV-1 
virions from reservoirs such as microglial cells, 
macrophages and dendritic cells. It is observed that even 
though the HAART dose rate D is increased to 4000 units, 
there is a subsequent therapeutic failure because the 
non-infected CD4+ cell number plummets as HIV-1 virions 
overwhelm the immune system. On the other hand, the 
adoptive transferred 2000 units of CD8+ cells are able to 
keep the Kaposi sarcoma cancer cells under the clinically 
detectable level of 1000 cells.    
 
(iv) Hypothetical clinical case #4 [Figure 2, P2′]: 
The physiological parametric configuration is the same as 
that of P2 except for the fact that the HAART drug dose rate 
D is increased to 5000 units, and the non-infected CD4+ T 
cells (x1) are given an extra boost of interleukin-2 (IL-2) 
dose and as such the value of a1 is now 0.45. The outcome 
is clinically efficacious because the plasma HIV-1 virions 
(x3), the HIV-1 infected CD4+ T cells (x2), and the KS 
cancer cells are kept under the clinically detectable level of 
1000 cells, whereas the non-HIV-1 infected CD4+ T cells 
(x1) repopulate to clinically efficacious level.    
5 Summary 
Our research can be summarized in the following 
statements: 
(i) It is possible for HAART therapy to annihilate the HIV 
virions without necessarily eliminating KS. 
(ii) Adoptive transfer of CD8+ T cells at a predetermined 
dose rate can annihilate KS cancer cells. 
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(iii) It will require both HAART and adoptive transfer CD8+ 
T cells incubated with IL-2 to decimate both HIV-1 
virions and the Kaposi sarcoma cancer cells. 
 
TABLE 1. Hypothetical AIDS Patient Parametric Configuration Ρ1 
S1 = 800 /day/μl 
a1 = 0.15 /day/cell/μl 
b1 = 0.01 /cell/μl 
α1 = 
0.5/day/virions/μl 
k1 = 0.0005/day/μl 
q1 = 
0.00045/day/μl/cell 
e10 =  
0.0025 cells/day/μl 
x10 = 500 cells/μl 
S2 = 800 /day/μl 
a2 = 0.11 /day/cell/μl 
b2 = 0.004/cell/μl 
α2= 0.5/day/virions/μl 
k2 = 0.005/day/μl 
q2 = 0.00001/day/μl/cell β1 = 1.5 
virions/CD4+/day 
K1 = 0.0001/day/μl 
e20 = 0.0005 cells/day/μl 
x20 = 400 cells/μl 
S3 = 10 /day/μl β2 = 
0.0085virions/CD4+/day/μl 
β3 = 2.75 virions/CD4+/day 
α3 = 0.027 /day/virions/μl 
k3 = 0.0001/day 
e30 = 0.0001 /day 
η1 = 0.055 ξ2 = 0.85 ξ3 = 0.0001 
x30 = 1000 virions/μl 
S4 = 10 /day/μl 
a4 = 0.35 
/day/cell/μl 
b4 = 0.01/cell/μl 
K2 = 0.0024 /day/μl 
k4 = 0.08/day/μl 
e40 = 0.0002 
cells/day/μl 
η2 = 0.055 
γ4 = 0.15 
x40 = 1500 cells/μl 
D = 4000 units 
σ0 = 0.5 mg/day σ2 = 30 mg/day σ3 = 5 mg/day λ0 = 5 mg/L λ2 = 10 mg/L λ3 = 0.015 mg/L 
x50 = 1500 
cells/μl 
n = 5 
c1 = 6.405 
c2 = 0.00075 σ4 = 7 mg/day λ4 = 5.5 mg/L 
x60 = 
2500cells 
 
 
   
     
Figure 1 Simulation results using parametric configurations Ρ1 vs. P1′  
(P1′ is the modified P1: same as Ρ1 except S4 = 2000. The time axis unit is months.) 
TABLE 2. Hypothetical AIDS Patient Parametric Configuration Ρ2 
S1 = 800 /day/μl 
a1 = 0.15 /day/cell/μl 
b1 = 0.01 /cell/μl 
α1 = 
0.5/day/virions/μl 
k1 = 0.0005/day/μl 
q1 = 
0.00045/day/μl/cell 
e10 = 0.0025 
cells/day/μl 
x10 = 500 cells/μl 
S2 = 800 /day/μl 
a2 = 0.11 /day/cell/μl 
b2 = 0.004/cell/μl 
α2= 0.5/day/virions/μl 
k2 = 0.005/day/μl 
q2 = 0.00001/day/μl/cell β1 = 1.5 
virons/CD4+/day 
K1 = 0.0001/day/μl 
e20 = 0.0005 cells/day/μl 
x20 = 400 cells/μl 
 
S3 = 1000 /day/μl β2 = 0.0085 
virons/CD4+/day/μl 
β3 = 2.75 virions/CD4+/day 
α3 = 0.027/day/virions/μl 
k3 = 0.0001/day 
e30 = 0.0001 /day 
η1 = 0.055 ξ2 = 0.85 ξ3 = 0.0001 
x30 = 1000 virions/μl 
S4 = 2000 /day/μl 
a4 = 0.35 
/day/cell/μl 
b4 = 0.01/cell/μl 
K2 = 0.0024 /day/μl 
k4 = 0.08/day/μl 
e40 = 0.0002 
cells/day/μl 
η2 = 0.055 
γ4 = 0.15 
x40 = 1500 cells/μl 
D = 4000 units 
σ0 = 0.5 mg/day σ2 = 30 mg/day σ3 = 5 mg/day λ0 = 5 mg/L λ2 = 10 mg/L λ3 = 0.015 mg/L 
x50 = 1500 
cells/μl 
n = 5 
c1 = 6.405 
c2 = 0.00075 σ4 = 7 mg/day λ4 = 5.5 mg/L 
x60 = 
2500cells 
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Figure 2 Simulation results using parametric configurations Ρ2 vs. P2′  
(P2′ is the modified P2: same as Ρ2 except a1=0.45, D=5000.The time axis unit is months.) 
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